Growth Metrics

Aytu Biopharma (AYTU) Cost of Revenue (2016 - 2026)

Aytu Biopharma has reported Cost of Revenue over the past 12 years, most recently at $5.5 million for Q4 2025.

  • Quarterly Cost of Revenue rose 1.95% to $5.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.3 million through Dec 2025, up 5.5% year-over-year, with the annual reading at $20.9 million for FY2025, 5.33% down from the prior year.
  • Cost of Revenue was $5.5 million for Q4 2025 at Aytu Biopharma, up from $5.3 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $15.7 million in Q2 2022 and troughed at $3.7 million in Q1 2024.
  • The 5-year median for Cost of Revenue is $5.7 million (2024), against an average of $7.8 million.
  • Year-over-year, Cost of Revenue soared 129.79% in 2021 and then plummeted 63.32% in 2024.
  • A 5-year view of Cost of Revenue shows it stood at $9.7 million in 2021, then dropped by 6.98% to $9.0 million in 2022, then plummeted by 53.87% to $4.1 million in 2023, then surged by 31.12% to $5.4 million in 2024, then grew by 1.95% to $5.5 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Cost of Revenue are $5.5 million (Q4 2025), $5.3 million (Q3 2025), and $4.8 million (Q2 2025).